Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Alva

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
The Journal of Urology|April 15, 2021
Reply by AuthorsKenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
Urologic Oncology|January 26, 2021
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitorsVincent T Ma, Christopher T Su, Miriam Hu, et al.
Urologic Oncology|December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapyPetros Grivas, Tarek A Bismar, Aijai S Alva, et al.
Cancer Research|August 24, 2018
Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate CancerLanbo Xiao, Jean C Tien, Josh Vo, et al.
Clinical Genitourinary Cancer|September 20, 2017
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract TumorsJorge D Ramos, Jonathan T Wingate, Roman Gulati, et al.
Cancer Research|December 17, 2015
Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted TherapyAndrew S McDaniel, Daniel H Hovelson, Andi K Cani, et al.
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
Medical Oncology (Northwood, London, England)|February 15, 2021
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcomeEman Abdulfatah, Zachery R Reichert, Matthew S Davenport, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumI Stukalin, J C Wells, J Graham, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
The Journal of Urology|April 15, 2021
Reply by AuthorsKenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
Urologic Oncology|January 26, 2021
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitorsVincent T Ma, Christopher T Su, Miriam Hu, et al.
Urologic Oncology|December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapyPetros Grivas, Tarek A Bismar, Aijai S Alva, et al.
Cancer Research|August 24, 2018
Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate CancerLanbo Xiao, Jean C Tien, Josh Vo, et al.
Clinical Genitourinary Cancer|September 20, 2017
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract TumorsJorge D Ramos, Jonathan T Wingate, Roman Gulati, et al.
Cancer Research|December 17, 2015
Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted TherapyAndrew S McDaniel, Daniel H Hovelson, Andi K Cani, et al.
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
Medical Oncology (Northwood, London, England)|February 15, 2021
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcomeEman Abdulfatah, Zachery R Reichert, Matthew S Davenport, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumI Stukalin, J C Wells, J Graham, et al.
Pageof 8